ACER Stock Overview Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Acer Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Acer Therapeutics Historical stock prices Current Share Price US$0.80 52 Week High US$4.56 52 Week Low US$0.55 Beta 0.44 1 Month Change -2.73% 3 Month Change 21.88% 1 Year Change -30.04% 3 Year Change -70.42% 5 Year Change -96.75% Change since IPO -91.99%
Recent News & Updates
Acer Therapeutics Inc. Files Form 15 Nov 30 Acer Therapeutics Inc. Announces Executive Changes
Nasdaq to Delist the Securities of Acer Therapeutics Nov 18
Acer Therapeutics Inc. announced delayed 10-Q filing Nov 16
Acer Therapeutics Inc. announced delayed 10-Q filing Nov 15
Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index Nov 13 See more updates
Acer Therapeutics Inc. Files Form 15 Nov 30 Acer Therapeutics Inc. Announces Executive Changes
Nasdaq to Delist the Securities of Acer Therapeutics Nov 18
Acer Therapeutics Inc. announced delayed 10-Q filing Nov 16
Acer Therapeutics Inc. announced delayed 10-Q filing Nov 15
Acer Therapeutics Inc.(OTCPK:ACER) dropped from S&P TMI Index Nov 13 Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) entered into definitive Agreement to acquire Acer Therapeutics Inc. (NasdaqCM:ACER) for $91 million. Sep 01
Acer Therapeutics Receives a Letter from Nasdaq Indicating the Company Is Not in Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market Jun 09
Acer Therapeutics Inc. Receives Non-Compliance Notice From Nasdaq May 05
Acer Therapeutics Announces Full Enrollment of Phase 2A Trial of Acer-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause Feb 15
Acer Therapeutics Inc. Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate Jan 06
Acer Therapeutics Compliant with All Nasdaq Listing Criteria Dec 30 Acer Therapeutics Inc. announced that it has received $1.5 million in funding Dec 06
Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.23 loss in 3Q 2021) Nov 17
Insufficient new directors Nov 16
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol) Oct 27
Acer Therapeutics Inc. Announces Receipt of Notice of Allowance of US Patent Application Covering Kit Comprising Phenylbutyrate and Sodium Benzoate Oct 16
Acer Therapeutics Inc. Announces Expansion of Acer-801 (Osanetant) Development Indications to Include Post-Traumatic Stress Disorder Oct 06
Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment Oct 05
First half 2022 earnings released: US$0.80 loss per share (vs US$0.54 loss in 1H 2021) Aug 17
RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease Aug 13
Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU Aug 12 Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy Jul 28
Acer resubmits U.S. marketing application for urea cycle disorder therapy Jul 18
Acer Therapeutics Inc. Resubmittes the ACER-001 New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders Jul 18
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome Jun 28 Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001
Acer Therapeutics Not Yet Received Decision from the U.S. Food and Drug Administration on ACER-001 Jun 10
Acer Therapeutics Receives a Letter from the Listing Qualifications Department Staff of the Nasdaq Stock Market Regarding Minimum Market Value of Listed Securities Jun 01
Consensus forecasts updated May 23
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 18
Acer Therapeutics Inc. Provides an Update on the Recent Corporate Developments May 17 Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients May 10
Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference May 08
Insufficient new directors Apr 27
Acer Therapeutics Inc., Annual General Meeting, May 20, 2022 Apr 16
Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Apr 12
Acer Therapeutics’ EDSIVO Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome Apr 06
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard Apr 01
Acer Therapeutics Enrolls First Patient in Its Phase 2A Clinical Trial of Acer-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause Mar 31
Consensus revenue estimates fall by 29% Mar 09
Acer Therapeutics Inc. Announces Appointment of Adrian Quartel as Chief Medical Officer Feb 24
Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth Feb 11
No longer forecast to breakeven Jan 14
Acer Therapeutics Inc. Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms Dec 10
Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases Aug 31
Consensus forecasts updated Aug 12
Acer Therapeutics Plans Clinical Trial for Edsivo Following Type B FDA Meeting Jun 11
Acer Expands Its Predator Gaming Portfolio with Three New HDR Monitors May 28
Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA May 26
Consensus revenue estimates increase to US$8.00m May 25
We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate May 20
Acer Therapeutics Inc. Announces Update on Settlement of Derivative Suits Mar 27
Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares Feb 25
Acer Therapeutics Inc. Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions Feb 13
Relief Therapeutics and Acer Therapeutics Sign Option Agreement to Pursue a Potential Collaboration and License Arrangement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease Jan 28
New 90-day high: US$3.85 Jan 16
Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders Dec 22
Acer Therapeutics Inc. Announces Publication of Additional Long-Term Data from COL3A1-Positive Vascular Ehlers-Danlos Syndrome (vEDS) Patients Dec 19
New 90-day low - US$2.44 Sep 06
New 90-day high - US$5.41 Aug 08
Acer Therapeutics Inc. announced that it expects to receive $0.857493 million in funding Jul 31
Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell 2000 Dynamic Index Jul 04 Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Small Cap Completeness Index Acer Therapeutics Inc.(NasdaqCM:ACER) dropped from Russell Microcap Index Shareholder Returns ACER US Pharmaceuticals US Market 7D -5.4% -1.9% -2.8% 1Y -30.0% 2.7% 24.1%
See full shareholder returns
Return vs Market: ACER underperformed the US Market which returned 15.2% over the past year.
Price Volatility Is ACER's price volatile compared to industry and market? ACER volatility ACER Average Weekly Movement 32.3% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ACER's share price has been volatile over the past 3 months.
Volatility Over Time: ACER's weekly volatility has increased from 23% to 32% over the past year.
About the Company Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company’s pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.
Show more Acer Therapeutics Inc. Fundamentals Summary How do Acer Therapeutics's earnings and revenue compare to its market cap? ACER fundamental statistics Market cap US$19.68m Earnings (TTM ) -US$38.76m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ACER income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$38.76m Earnings -US$38.76m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -1.58 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -96.4%
How did ACER perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/11/20 07:44 End of Day Share Price 2023/11/17 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Acer Therapeutics Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Constantine Davides D. Boral Capital LLC. Vernon Bernardino H.C. Wainwright & Co.
Show 5 more analysts 
